Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company`s 1st Annual Neuroscience Forum and Oppenheimer`s 32nd Annual Healthcare Conference, taking place March 16th, 2022 at 9:30am ET and March 17th, 2022 at 1:20pm ET, respectively. Please find additional details about the events below.
Needham & Company`s 1st Annual Neuroscience Forum (virtual)
Date: Wednesday, March 16, 2022, 9:30-10:10am ET
Webcast: https://wsw.com/webcast/needham118/rlmd/2253300
Oppenheimer`s 32nd Annual Healthcare Conference (virtual)
Date: Thursday, March 17, 2022, 1:20-1:50pm ET
Webcast: https://wsw.com/webcast/oppenheimer20/rlmd/2773890
The webcasts can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. Archived replays will be available for 90 days after the conclusion of the events.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada`s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada`s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.
About REL-1017
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD. The ongoing RELIANCE Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated robust, rapid, and sustained antidepressant effects with statistically significant improvements compared to placebo. The Phase 2 study also showed a favorable pharmacokinetic, safety, and tolerability profile of REL-1017 consistent with results observed in previously completed Phase 1 studies.